关于思创医惠科技股份有限公司 2026 年第一次临时股东会的 法律意见 杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 邮编：310020 电话：(+86)0571-86508080 传真：(+86)0571-87357755 北京德恒（杭州）律师事务所 北京德恒（杭州）律师事务所 关于思创医惠科技股份有限公司 2026年第一次临时股东会的法律意见 北京德恒（杭州）律师事务所 关于思创医惠科技股份有限公司 2026 年第一次临时股东会的 法律意见 德恒【杭】书 2026 第 01017 号 致：思创医惠科技股份有限公司 北京德恒（杭州）律师事务所（以下简称"本所"）受思创医惠科技股份有 限公司（以下简称"思创医惠"或"公司"）委托，指派娄建江律师、朱浩齐律 师（以下简称"承办律师"）出席公司 2026 年第一次临时股东会（以下简称"本 次股东会"），对本次股东会的合法性进行见证并出具法律意见。 本法律意见根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《股东会规则》"）和《深圳证券交易所上市公司股 ...

思创医惠科技股份有限公司（以下简称"公司"）股票于 2026 年 1 月 13 日、2026 年 1 月 14 日连续两个交易日内日收盘价格涨幅偏离值累计超过 30%， 根据《深圳证券交易所交易规则》的有关规定，属于股票交易异常波动的情况。 二、公司关注、核实情况的说明 证券代码：300078 证券简称：思创医惠 公告编号：2026-001 思创医惠科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 针对公司股票交易异常波动情形，公司董事会通过自查、电话及函询等方式， 对公司、公司第一大股东及其一致行动人就相关问题进行了核实，具体情况如下： 3、公司近期经营情况及内外部经营环境未发生重大变化，公司生产经营正 常； 4、公司管理层收购暨公司控制权拟发生变更事项。公司于 2025 年 11 月 18 日在巨潮资讯网（www.cninfo.com.cn，下同）披露了《关于重新签署<股份转让 协议><表决权委托协议>构成管理层收购暨公司控制权拟发生变更和权益变动的 提示性公告》（公告编号：2025-1 ...

据天眼查APP显示，思创医惠科技股份有限公司成立于2003年11月21日，注册资本111787.223万人民 币。（数据宝） （文章来源：证券时报网） 数据宝统计，截至10:52，思创医惠成交额16.26亿元，创2025年2月18日以来新高。最新股价上涨 9.15%，换手率23.74%。上一交易日该股全天成交额为12.09亿元。 ...

Strong Stocks - As of January 13, the Shanghai Composite Index fell by 0.64% to 4138.76 points, the Shenzhen Component Index decreased by 1.37% to 14169.4 points, and the ChiNext Index dropped by 1.96% to 3321.89 points [1] - A total of 75 stocks in the A-share market hit the daily limit, with the top three strong stocks being: Luxin Venture Capital (600783), Hangxiao Steel Structure (600477), and Julong Cable (002342) [1] - Detailed data for the top 10 strong stocks includes: - Luxin Venture Capital (600783): 13 days with 11 limit-ups, turnover rate of 20.18%, and closing price of 54.9 - Hangxiao Steel Structure (600477): 4 consecutive limit-ups, turnover rate of 15.79%, and closing price of 16.3 - Julong Cable (002342): 4 consecutive limit-ups, turnover rate of 39.34%, and closing price of 48.2 [1] Strong Concept Sectors - The top three concept sectors with the highest gains in the A-share market are: AI Applications, CRO Concept, and Cell Immunotherapy [2] - Detailed data for the top 10 concept sectors includes: - AI Applications: increased by 10.3% - CRO Concept: increased by 3.56% - Cell Immunotherapy: increased by 2.92% [3]

思创医惠今日涨停，全天换手率20.58%，成交额12.09亿元，振幅20.34%。龙虎榜数据显示，机构净买 入237.35万元，营业部席位合计净买入9253.11万元。 融资融券数据显示，该股最新（1月12日）两融余额为1.70亿元，其中，融资余额为1.70亿元，融券余额 为26.58万元。近5日融资余额合计增加1407.95万元，增幅为9.06%，融券余额合计增加5.86万元，增幅 28.29%。（数据宝） 思创医惠1月13日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 开源证券股份有限公司西安西大街证券营业部 | 7178.09 | 46.36 | | 买二 | 东方证券股份有限公司杭州金鸡路证券营业部 | 4495.49 | 0.00 | | 买三 | 东方证券股份有限公司扬州文汇东路证券营业部 | 2360.21 | 0.00 | | 买四 | 华鑫证券有限责任公司上海虬江路证券营业部 | 2134.37 | 0.00 | | 买五 | 机构专用 | 2110.83 | 1968.58 | ...

市场分析认为，本轮行情核心驱动力在于产业趋势的明确确认。一方面，蚂蚁集团旗下的AI健康助 手"蚂蚁阿福"自发布后短期内月活用户突破3000万，单日提问量超千万，验证了健康AI赛道的巨大需求 和市场想象力。 与此同时，继"蚂蚁阿福"后，OpenAI于1月8日正式推出健康功能"ChatGPT Health"，标志着全球顶尖AI 公司一致看好并重仓健康AI赛道。市场观点指出，拥有成熟场景、与领先AI应用形成生态合作的医疗 健康公司，有望在此轮产业浪潮中持续受益。 今日，AI医疗与制药概念板块持续拉升，呈现井喷行情。板块内多只个股涨停，其中与"蚂蚁阿福"相关 的概念股成为绝对主线，表现最为强劲。华人健康、思创医惠收获"20厘米"涨停；美年健康、迪安诊断 双双录得连续第三个涨停板，卫宁健康等多只个股涨幅超过10%。 统计显示，自蚂蚁阿福2015年12月中旬面世以来，其生态辐射效应持续释放，相关概念股迎来重估。其 中，华人健康股价涨幅已接近翻倍，卫宁健康涨超80%，美年健康涨超50%。 ...

Core Viewpoint - The AI healthcare and pharmaceutical sectors are experiencing significant upward momentum, with multiple stocks reaching their daily limit up. Group 1: Stock Performance - Chinese Health (301408) and Sichuang Medical (300078) both hit the 20% daily limit up [1] - Other stocks such as Xin Ganjiang, Boji Pharmaceutical (300404), Nossger (301333), Puris (301257), and Dian Diagnostics (300244) also reached their daily limit up [1] - Companies like Okon Pharmaceutical, Rongchang Bio, Weining Health (300253), and BGI Genomics (300676) saw their stock prices increase by over 10% [1]

Core Viewpoint - The Shenzhen Stock Exchange has issued multiple penalties related to the convertible bond project of Sichuan Medical Technology Co., Ltd. (300078), highlighting issues of non-operational fund occupation and information disclosure violations by major shareholders and related parties [1] Group 1: Penalties and Disciplinary Actions - Sichuan Medical Technology and related parties received disciplinary actions from the Shenzhen Stock Exchange due to violations, including a public reprimand [1] - Citic Securities, the sponsor for the convertible bond project, and Tianjian Accounting Firm also received penalties, with their representatives facing similar disciplinary actions [1] - This marks the first instance of a securities company receiving a regulatory letter from the Shenzhen Stock Exchange since the implementation of the registration system in the ChiNext board [1] Group 2: Investigation Findings - Citic Securities failed to adequately address multiple inquiries from the Shenzhen Stock Exchange regarding fund occupation and prepayment issues, leading to the issuance of a false commitment letter [2] - From 2018 to 2020, the major shareholder, Hangzhou Sichuan Medical Technology Group Co., Ltd., and its affiliates occupied a total of 338.457 million yuan in funds, with a maximum daily balance of 200.5015 million yuan [2] - Although the occupied funds were returned by April 30, 2021, the Shenzhen Stock Exchange had previously requested Citic Securities to verify the existence of non-operational fund occupation [2] Group 3: Due Diligence Failures - Citic Securities conducted a series of misleading operations, failing to properly investigate the purpose and accounting treatment of prepayments and investments, despite being aware of significant anomalies [3][4] - The firm issued a commitment letter that inaccurately stated there were no fund occupations by major shareholders, contradicting the actual situation [3] - The Shenzhen Stock Exchange criticized Citic Securities for not following due diligence standards and for providing inaccurate verification opinions [4] Group 4: Audit Firm Responsibilities - Tianjian Accounting Firm, responsible for the annual audits and the convertible bond project, also faced scrutiny for not adequately identifying and assessing the risks of fund occupation [6] - The firm failed to maintain reasonable professional skepticism and did not verify the flow of funds despite clear indications of potential issues [6] - The Shenzhen Stock Exchange noted that Tianjian's audit measures were insufficient, primarily relying on contract reviews and management interviews without proper verification of fund flows [6] Group 5: Regulatory Environment - The issue of fund occupation has been a recurring topic in the sponsorship work, with recent regulatory revisions aimed at enhancing the quality of due diligence in securities issuance [7] - The new regulations emphasize the need for sponsors to investigate the reasons and rationality behind receivables from related parties, particularly concerning potential fund occupations [7] - Regulatory bodies have been intensifying quality control measures for various investment banking projects, indicating a stricter oversight environment [7]

Core Viewpoint - Sichuang Medical Technology Co., Ltd. is facing legal scrutiny for alleged fraudulent issuance of securities and violations of information disclosure, with the case now moving to prosecution stage [1][2][3]. Group 1: Legal Proceedings - The Hangzhou Public Security Bureau has concluded its investigation into Sichuang Medical, confirming clear criminal facts and sufficient evidence, and has transferred the case to the Hangzhou People's Procuratorate for prosecution [1]. - Sichuang Medical has received a notice from the Hangzhou Public Security Bureau requesting evidence related to the case, indicating ongoing legal processes [1]. Group 2: Company Operations - Despite the legal issues, Sichuang Medical claims that its production and operational activities are running normally and that the legal proceedings will not impact its business operations [2]. - The company is committed to cooperating with the legal authorities and aims to protect the legal rights of the company and its shareholders [2]. Group 3: Regulatory Actions - The Zhejiang Securities Regulatory Bureau has proposed administrative penalties against Sichuang Medical for fraudulent issuance and information disclosure violations, including a fine of 81.7 million yuan (approximately 8.17 million) for fraudulent fundraising [3][4]. - The regulatory body has also indicated that the former chairman and general manager, Zhang Lizhong, will face a 10-year market ban due to the severity of the violations [4]. Group 4: Financial Background - Sichuang Medical has raised a total of 3.028 billion yuan (approximately 302.8 million) through five fundraising activities, including an initial public offering and multiple private placements [4]. - The company’s initial public offering raised 986 million yuan (approximately 98.6 million), with net proceeds of 934.08 million yuan (approximately 93.4 million) after expenses [5].

Core Viewpoint - The company, Sichuang Medical Technology Co., Ltd., is facing legal scrutiny for alleged fraudulent issuance of securities and improper disclosure of important information, with the case now moving to the prosecution stage [3][4][5]. Group 1: Legal Proceedings - The company received a notice from the Hangzhou Public Security Bureau regarding the transfer of the case to the Hangzhou People's Procuratorate for prosecution, indicating that the investigation has concluded with clear criminal facts and sufficient evidence [4][5]. - The case originated from the company's public issuance of convertible bonds amounting to 817 million yuan in 2021, during which it allegedly fabricated financial data for 2019 and 2020 through fictitious business activities and inflated revenue [5][6]. - The actual controller, Zhang Lizhong, has been banned from the market due to his role in orchestrating the financial fraud, which included concealing related party fund usage [6][7]. Group 2: Company Operations and Strategy - Despite the ongoing legal issues, the company claims that its production and operational activities are running normally and that it will cooperate with the legal proceedings while protecting the rights of its shareholders [4][5]. - The company is undergoing a transformation focusing on compliance and core business, with plans to optimize its name and business scope to reflect its strategic direction in the Internet of Things sector [4][7]. - As of the third quarter of 2025, the company reported a revenue of 604 million yuan, a year-on-year increase of 7%, while reducing its net loss from 284 million yuan to 4.76 million yuan [7][8].